OCLN Antibody

What is Occludin (OCLN) and why are antibodies against it important for research?

Occludin is a tetraspan transmembrane protein with two extracellular loops (EL1 and EL2), predominantly localized at tight junctions between epithelial and endothelial cells. OCLN antibodies are crucial research tools because:

• OCLN plays a vital role in the formation and regulation of the tight junction paracellular permeability barrier

• It functions as a coreceptor for hepatitis C virus (HCV) in hepatocytes

• OCLN maintains blood-brain barrier integrity

• It participates in cellular adhesion, signal transduction, and cell migration processes

Dysregulation of OCLN expression or function has been implicated in numerous pathological conditions including inflammatory bowel disease, viral infections, and cancer .

What types of OCLN antibodies are available for research applications?

Several types of OCLN antibodies are currently available for research:

Most commercially available antibodies target the intracellular N- or C-terminal regions, while specialized monoclonal antibodies have been developed to target the extracellular loops with therapeutic potential .

What are the common applications for OCLN antibodies in basic research?

OCLN antibodies are employed in multiple experimental approaches:

• Western blot (WB): For detecting OCLN protein expression levels (typical dilution 1:500-1:5000)

• Immunohistochemistry (IHC): For visualizing OCLN in tissue sections (typical dilution 1:200-1:500)

• Immunofluorescence (IF): For subcellular localization studies (typical dilution 1:50-1:200)

• Flow cytometry: For analyzing cell surface expression of OCLN

• Immunoprecipitation: For isolating OCLN and associated protein complexes

• ELISA: For quantitative detection of OCLN

• Cell-based binding assays: For studying OCLN interactions

The choice of application determines which antibody format and detection method is most appropriate .

How can researchers validate the specificity of OCLN antibodies in their experimental systems?

Validating OCLN antibody specificity is critical for reliable results. Recommended approaches include:

• Knockout validation: Compare signal between wild-type and OCLN knockout cells. For example, ab31721 was validated using wild-type and OCLN knockout HAP1 cells, where the predicted 59 kDa band was absent in knockout samples .

• Epitope mapping: Use site-directed mutagenesis to identify critical residues for antibody recognition. Studies have shown that:

  • Small loop between two cysteines in the EL2 domain is essential for binding of EL2-recognizing mAbs

  • Three EL1-recognizing mAbs have overlapping but distinct recognition sites within EL1

• Differential screening: Test antibody binding in cells with different OCLN expression levels (e.g., CHO-K1 cells with undetectable OCLN vs. CHO-K1/hOCLN cells with transient OCLN expression)

• Cross-reactivity assessment: Test the antibody against multiple species to confirm specificity (note that some antibodies are human-specific, while others recognize both human and mouse OCLN)

How do researchers distinguish between antibodies targeting different extracellular loops of OCLN and why is this important?

Distinguishing between antibodies targeting EL1 versus EL2 is crucial because:

• Functional differences: EL2 accounts for species selectivity in HCV entry, with six amino acids differing between human and mouse OCLN. At least two alanine residues (A223 and A224) in EL2 are critical for HCV-sensitivity in host cells .

• Binding characteristics: Research has revealed that:

  • EL1-recognizing mAbs are typically applicable for immunoblotting, while EL2-recognizing mAbs may not be suitable for this application

  • EL2-recognizing mAbs can recognize both human and mouse OCLN, while EL1-recognizing mAbs may be human-specific

• Experimental detection methods:

  • Immunoprecipitation followed by immunoblotting with domain-specific antibodies

  • Mutagenesis studies that selectively modify EL1 or EL2 domains

  • Competitive binding assays with characterized antibodies of known specificity

What methodological approaches can researchers use to study OCLN's role in HCV infection using antibodies?

Several sophisticated methodologies using OCLN antibodies have been developed to study HCV infection:

• Kinetic studies with anti-OCLN and anti-CLDN1 mAbs:

  • HCVpp (HCV pseudoparticles) binding assays at 4°C followed by temperature shift to 37°C

  • Addition of mAbs at different time points before or after binding phase

  • These studies have demonstrated that OCLN interacts with HCV after CLDN1 in the internalization step

• Cell-free HCV infection inhibition assays:

  • Dose-dependent inhibition of HCV infection in Huh7.5.1-8 cells

  • Prevention of both cell-free HCV infection and cell-to-cell HCV transmission

• In vivo HCV infection models:

  • Use of human liver chimeric mice

  • Administration of anti-OCLN mAbs to prevent HCV infection without apparent adverse effects

• Differential binding assays:

  • Using cells with varied OCLN expression: Huh7.5.1-8 cells (express intact hOCLN) versus OKH-4 cells (defective hOCLN expression)

What factors should researchers consider when using OCLN antibodies for tight junction permeability studies?

When investigating tight junction permeability with OCLN antibodies, researchers should consider:

• Potential functional interference:

  • Some antibodies may disrupt tight junction barrier function while others do not

  • Anti-OCLN mAbs were tested using transwell culture systems with polarized Caco-2 cells to confirm they did not disrupt the epithelial TJ barrier

• Accessibility considerations:

  • Tight junctions are typically located at the apical-lateral membrane interface

  • Some anti-OCLN mAbs are accessible to OCLN from the basolateral side of hepatocytes but not from the apical side

• Combined methodological approaches:

  • Transepithelial/transendothelial electrical resistance (TEER) measurements

  • Paracellular flux assays using fluorescently labeled dextrans or other tracers

  • Immunolocalization of OCLN and other tight junction proteins before and after antibody treatment

• Physiological relevance:

  • Consider differences between in vitro and in vivo tight junction organization

  • Account for tissue-specific tight junction composition and regulation

Why might researchers observe multiple bands when performing Western blots with OCLN antibodies?

Multiple bands in OCLN Western blots are commonly observed and may be attributed to:

• Post-translational modifications:

  • Phosphorylation at multiple sites

  • Ubiquitination and subsequent degradation

  • Glycosylation patterns

• Proteolytic processing:

  • Several host enzymes reportedly cleave OCLN at multiple sites in different cell types

  • For example, researchers noted bands smaller than the predicted ~62kD full-length OCLN band, which could represent truncated forms of OCLN

• Isoform expression:

  • Multiple splice variants may be expressed in different tissues

  • Alternative start codons can generate proteins of different sizes

• Experimental considerations:

  • Sample preparation techniques (reducing vs. non-reducing conditions)

  • Lysis buffer composition and protease inhibitors used

  • Sample heating conditions (time and temperature)

What strategies can researchers employ to optimize immunodetection of OCLN's extracellular domains?

Optimizing detection of OCLN's extracellular domains requires specialized approaches:

• Antibody generation strategies:

  • Genetic immunization methods have proven more successful than conventional approaches

  • DNA immunization with expression vectors encoding hOCLN followed by cell differential screening has successfully generated anti-OCLN mAbs against intact extracellular domains

• Cell-based screening approaches:

  • Use of paired cell lines: one expressing OCLN and one with minimal/no OCLN expression

  • For example, CHO-K1 cells (undetectable OCLN) versus CHO-K1/hOCLN cells (expressing hOCLN)

• Fixation and permeabilization optimization:

  • Live cell staining for surface epitopes

  • Careful fixation that preserves extracellular epitopes

  • Mild detergents that maintain membrane protein conformation

• Detection systems:

  • Signal amplification techniques for low abundance epitopes

  • Direct versus indirect detection methods

  • Specialized cell-based ELISA approaches for quantification

How can researchers address challenges in detecting OCLN in different tissue and cell types?

OCLN detection varies across tissues and cell types due to expression levels and cellular localization. Strategies to address these challenges include:

• Tissue-specific optimization:

  • Antigen retrieval methods: Different tissues may require specific retrieval protocols

  • For example, paraffin-embedded human colon cancer tissue stained for Occludin using ab235986 requires high-pressure antigen retrieval

• Cell type-specific considerations:

  • Hepatocytes (e.g., Huh7.5.1-8, HepG2) express higher levels of OCLN compared to some other cell types

  • Human breast adenocarcinoma cell line (MCF7) requires specific antibody dilutions (1/500 for ab235986)

• Sample preparation techniques:

  • Whole cell lysates versus membrane fraction enrichment

  • Different lysis buffers for various tissue types

  • Specific protease inhibitor cocktails to prevent degradation

• Detection sensitivity adjustments:

  • Antibody concentration optimization (e.g., 1/400 dilution for IHC-P with ab235986)

  • Enhanced chemiluminescence systems for low abundance detection

  • Signal amplification methods for tissues with minimal OCLN expression

How are OCLN antibodies being utilized in developing anti-HCV therapeutic strategies?

OCLN antibodies show significant potential as anti-HCV therapeutics:

• Monoclonal antibody development:

  • Anti-OCLN mAbs with very high affinity (antibody dissociation constant <1 nM) have been developed

  • These mAbs recognize the first or second extracellular loop of human OCLN

  • All developed mAbs inhibited HCV infection in Huh7.5.1-8 cells in a dose-dependent manner without apparent cytotoxicity

• Smaller antibody fragment development:

  • Conversion of anti-OCLN mAbs to corresponding Fab fragments and scFv antibodies

  • These smaller fragments maintain similar binding specificity and affinity to parental mAbs

  • Both Fab fragments and scFv antibodies successfully inhibit in vitro HCV infection

• In vivo efficacy studies:

  • Selected mAbs completely inhibited HCV infection in human liver chimeric mice

  • No apparent adverse effects were observed, suggesting therapeutic potential

• Combination therapy approaches:

  • Anti-OCLN mAbs could be promising candidates for novel anti-HCV agents, particularly in combination with direct-acting HCV antiviral agents

What considerations are important when using OCLN antibodies to study blood-brain barrier integrity?

OCLN antibodies are valuable tools for blood-brain barrier (BBB) research, with important considerations:

How can researchers use OCLN antibodies to investigate the relationship between tight junction disruption and disease pathogenesis?

OCLN antibodies enable detailed investigation of tight junction pathobiology:

• Disease-specific applications:

  • Inflammatory bowel disease: OCLN expression and localization studies

  • Cancer research: Examining tight junction breakdown during metastasis

  • Viral infections: Understanding mechanisms of tight junction disruption during pathogen entry

• Mechanistic studies:

  • Immunoprecipitation using anti-OCLN antibodies to identify disease-specific interaction partners

  • Time-course studies of OCLN localization during disease progression

  • Combined analysis with signal transduction pathways that regulate tight junction assembly/disassembly

• Therapeutic intervention assessment:

  • Monitoring OCLN expression and localization after drug treatment

  • Using anti-OCLN antibodies as both diagnostic tools and potential therapeutics

  • Evaluating barrier restoration in response to tight junction modulators

• Translational applications:

  • Comparing OCLN patterns between animal models and human disease tissues

  • Developing biomarkers for tight junction dysfunction based on OCLN detection

  • Screening for compounds that restore proper OCLN localization in disease states

What novel applications are emerging for engineered OCLN antibody fragments in research and therapeutics?

Engineered OCLN antibody fragments present exciting new research opportunities:

• Advanced therapeutic applications:

  • Smaller Fab and scFv fragments may offer improved tissue penetration

  • These fragments maintain similar binding specificity and affinity to parental mAbs

  • Potential for development as drug candidates for HCV and other OCLN-related pathologies

• Bispecific antibody approaches:

  • Targeting multiple tight junction proteins simultaneously (e.g., OCLN and CLDN1)

  • Combining OCLN targeting with immune cell recruitment

  • Creating molecules that can modulate tight junction function in a controlled manner

• Imaging applications:

  • Fluorescently labeled antibody fragments for live imaging of tight junction dynamics

  • PET/SPECT imaging agents for in vivo assessment of tight junction integrity

  • Nanoparticle-conjugated fragments for targeted drug delivery to tight junctions

• High-throughput screening platforms:

  • Using OCLN-binding fragments to develop screening assays for tight junction modulators

  • Cell-based reporter systems incorporating OCLN-binding domains

  • Biosensor development for real-time monitoring of tight junction status

How might advances in OCLN antibody development contribute to understanding epithelial-mesenchymal transition in cancer progression?

OCLN antibodies offer valuable insights into epithelial-mesenchymal transition (EMT):

• Dynamic regulation studies:

  • Real-time monitoring of OCLN downregulation during EMT

  • Correlation between OCLN localization changes and acquisition of mesenchymal phenotypes

  • Investigation of post-translational modifications of OCLN during cancer progression

• Mechanistic investigations:

  • Immunoprecipitation studies to identify EMT-specific OCLN interaction partners

  • Analysis of OCLN degradation pathways activated during EMT

  • Screening for EMT modulators that alter OCLN expression or localization

• Therapeutic targeting approaches:

  • Development of antibodies that stabilize epithelial phenotype by preserving OCLN function

  • Identification of epitopes that become exposed during early EMT as therapeutic targets

  • Combined targeting of multiple tight junction proteins during cancer treatment

• Biomarker development:

  • Quantification of soluble OCLN fragments as potential EMT biomarkers

  • Correlation of OCLN status with other EMT markers and clinical outcomes

  • Development of diagnostic assays to assess EMT status in tumor samples